---
figid: PMC10967338__antibodies-13-00025-g003
figtitle: Therapeutic tyrosine kinase inhibitors and anti-EGFR monoclonal antibodies
  in glioblastoma anti-EGFR mAbs bind the EGFR extracellular domain, preventing EGFR
  dimerization and subsequent activation
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC10967338
filename: PMC10967338__antibodies-13-00025-g003.jpg
figlink: /pmc/articles/PMC10967338/figure/F3
number: F3
caption: Therapeutic tyrosine kinase inhibitors and anti-EGFR monoclonal antibodies
  in glioblastoma anti-EGFR mAbs bind the EGFR extracellular domain, preventing EGFR
  dimerization and subsequent activation. Tyrosine kinase inhibitors (TKIs) target
  the intracellular TK domain, blocking subsequent receptor tyrosine kinase pathways
  (RTKs)
papertitle: 'vNARs as Neutralizing Intracellular Therapeutic Agents: Glioblastoma
  as a Target'
reftext: Alejandro Manzanares-Guzm√°n, et al. Antibodies (Basel). 2024 Mar;13(1).
year: '2024'
doi: 10.3390/antib13010025
journal_title: Antibodies
journal_nlm_ta: Antibodies (Basel)
publisher_name: MDPI
keywords: cancer immunotherapy | glioblastoma | molecular targeted therapy | variable
  new antigen receptors (vNARs) | intrabodies | receptor tyrosine kinase
automl_pathway: 0.8525152
figid_alias: PMC10967338__F3
figtype: Figure
redirect_from: /figures/PMC10967338__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC10967338__antibodies-13-00025-g003.html
  '@type': Dataset
  description: Therapeutic tyrosine kinase inhibitors and anti-EGFR monoclonal antibodies
    in glioblastoma anti-EGFR mAbs bind the EGFR extracellular domain, preventing
    EGFR dimerization and subsequent activation. Tyrosine kinase inhibitors (TKIs)
    target the intracellular TK domain, blocking subsequent receptor tyrosine kinase
    pathways (RTKs)
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - EGFR
  - EREG
  - BTC
  - TGFA
  - EGF
  - TK1
  - TK2
  - KRAS
  - HRAS
  - NRAS
  - XYLT2
  - SOS1
  - SOS2
  - GRB2
  - MTG1
  - PTEN
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - PDK1
  - PDPK1
  - STAT3
  - AKT1
  - AKT2
  - AKT3
  - TSC1
  - CCL26
  - TSC2
  - RHEB
  - RHEBP1
  - MTOR
  - RPTOR
  - Tyrosine kinase inhibitors
  - Erlotinib
  - Gefitinib
  - Dacomitinib
  - Afatinib
  - Neratinib
  - Ras
  - GDP
  - GTP
  - PIP3
  - Nucleus
  - Glioblastoma
---
